• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Topical analgesia for dyspareunia effective in breast cancer survivors

byMonica ParksandDavid Wang
August 1, 2015
in Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a randomized controlled trial of 46 breast-cancer survivors with dyspareunia, use of topical lidocaine in the vulvar vestibule immediately prior to intercourse demonstrated significantly improved sexual function compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Dyspareunia is common among post-menopausal women, and it is particularly problematic for survivors of breast cancer whose treatment involves a chronically estrogen-deficient state. This complication has a significant impact on quality of life. This study was a randomized, double-blind, placebo-controlled trial to compare the use of topical analgesia versus placebo in the treatment of dyspareunia in breast cancer survivors.

The study randomized 46 breast cancer survivors who reported chronic dyspareunia to topical 4% lidocaine versus normal saline during intercourse. This was followed by an open-label trial where all patients received lidocaine therapy. At the conclusion of this trial, users of lidocaine reported significantly reduced intercourse pain and sexual distress scores as well as significantly improved sexual function scores compared to placebo. Furthermore, during the open-label trial, 90% of all patients reported comfortable sexual function with topical lidocaine. There were no significant side effects associated with use of topical lidocaine and no male partners reported penile numbness. The results of this study support the use of symptomatic management in topical lidocaine in the management of dyspareunia in breast cancer survivors. The study was limited by a small cohort size. Furthermore, the study used subjective pain scores as the primary outcome, which limits the overall generalizability of the results. However, this study provides an interesting proof-of-concept for this topical analgesia therapy in this growing patient population.

Click to read the study in JCO

Relevant Reading: The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions

In-Depth [randomized controlled trial]: This study was a randomized, double-blinded, placebo-controlled trial comparing 4% aqueous lidocaine versus placebo in breast cancer survivors who experience chronic dyspareunia. Eligible patients were postmenopausal women with a history of >1 year of history breast cancer and moderate to severe dyspareunia for at least 6 months. Patients were excluded if they had a history of pelvic pain, pelvic floor myalgia, or vulvar dermatoses. A total of 46 women were enrolled and randomly assigned to 1 month of self-administered 4% lidocaine or placebo applied directly to the vulvar vestibule, immediately prior to intercourse. The primary outcomes were subjective patient assessment of intercourse pain scale (0 to 10). Secondary outcomes included sexual distress using the Female Sexual Distress Scale, and sexual function assessed by the Sexual Function Questionnaire. Following the randomized trial, all women then received open-label lidocaine for 2 months. At 6 months follow-up, patients in the lidocaine group had significantly decreased intercourse pain scores compared to control (1.0 vs. 5.3; p = 0.007). In assessments of sexual function, women in the lidocaine group had significant improvements in most domains compared to those in the placebo arm. After 2 months of lidocaine use during the open-label trial, 90% of all patients in the trial reported comfortable penetration.

RELATED REPORTS

Screening with digital breast tomosynthesis vs mammography associated with significantly lower risk of advanced breast cancer among women with extremely dense breasts at high risk of breast cancer

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Several factors influence health programs conducted in the African American Church

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: Breast CancerDyspareunia
Previous Post

Uterus transplant recipients report good psychological outcomes

Next Post

rVSV-ZEBOV Ebola vaccine highly effective and safe in trials conducted in Guinea

RelatedReports

2 Minute Medicine Rewind March 4, 2019
Chronic Disease

Screening with digital breast tomosynthesis vs mammography associated with significantly lower risk of advanced breast cancer among women with extremely dense breasts at high risk of breast cancer

June 16, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in  premenopausal women with ER+ breast cancer and ovarian suppression
StudyGraphics

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

May 3, 2022
Next Post
Ebola outbreak projected to exceed 20,000 cases by November

rVSV-ZEBOV Ebola vaccine highly effective and safe in trials conducted in Guinea

Picky eaters more likely to display psychiatric impairment

Picky eaters more likely to display psychiatric impairment

Concomitant HPV vaccine administration equivalent to staggered schedule

Concomitant HPV vaccine administration equivalent to staggered schedule

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.